Harbor Capital Advisors Inc. Buys 1,567 Shares of Soleno Therapeutics, Inc. $SLNO

Harbor Capital Advisors Inc. boosted its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 3.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 48,498 shares of the company’s stock after buying an additional 1,567 shares during the quarter. Harbor Capital Advisors Inc. owned 0.10% of Soleno Therapeutics worth $4,063,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in SLNO. AlphaQuest LLC lifted its holdings in shares of Soleno Therapeutics by 37.5% in the 1st quarter. AlphaQuest LLC now owns 983 shares of the company’s stock worth $70,000 after acquiring an additional 268 shares during the last quarter. Quarry LP purchased a new stake in Soleno Therapeutics in the 1st quarter worth about $121,000. Avanza Fonder AB lifted its stake in Soleno Therapeutics by 14.8% in the first quarter. Avanza Fonder AB now owns 1,951 shares of the company’s stock worth $144,000 after purchasing an additional 251 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of Soleno Therapeutics during the first quarter valued at approximately $232,000. Finally, GAMMA Investing LLC grew its stake in shares of Soleno Therapeutics by 4,377.3% during the first quarter. GAMMA Investing LLC now owns 3,358 shares of the company’s stock valued at $240,000 after buying an additional 3,283 shares during the last quarter. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Price Performance

Shares of NASDAQ SLNO opened at $49.71 on Wednesday. Soleno Therapeutics, Inc. has a fifty-two week low of $41.50 and a fifty-two week high of $90.32. The company has a market cap of $2.64 billion, a PE ratio of -12.01 and a beta of -2.72. The company has a debt-to-equity ratio of 0.21, a quick ratio of 15.01 and a current ratio of 15.13. The business has a 50-day simple moving average of $75.66 and a two-hundred day simple moving average of $71.87.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.44. The company had revenue of $32.66 million during the quarter, compared to analysts’ expectations of $3.91 million. As a group, equities analysts expect that Soleno Therapeutics, Inc. will post -3.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on SLNO. TD Cowen assumed coverage on Soleno Therapeutics in a report on Monday, June 23rd. They set a “buy” rating and a $110.00 price objective for the company. Wall Street Zen upgraded shares of Soleno Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 26th. Guggenheim reaffirmed a “buy” rating and issued a $106.00 price target on shares of Soleno Therapeutics in a research note on Wednesday, August 27th. Robert W. Baird set a $121.00 price objective on shares of Soleno Therapeutics and gave the company an “outperform” rating in a research report on Friday, July 11th. Finally, Oppenheimer raised their target price on shares of Soleno Therapeutics from $105.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $115.09.

Insider Buying and Selling at Soleno Therapeutics

In related news, insider Patricia C. Hirano sold 3,830 shares of the company’s stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $82.76, for a total value of $316,970.80. Following the transaction, the insider directly owned 13,206 shares of the company’s stock, valued at $1,092,928.56. This represents a 22.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.40% of the stock is owned by company insiders.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.